Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone in Schizophrenia/Schizoaffective Disorder with Type 2 Diabetes
NCT00395031Phase 3Completed
- Sponsor
- Manhattan Psychiatric Center
- Start
- Sep 2003
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ziprasidone in schizophrenia and schizoaffective disorder, sponsored by Manhattan Psychiatric Center. Primary endpoint: Reduced Glucose, Cholesterol and Lipid Levels at 11 weeks. Started Sep 2003; status: completed.
02
Drugs
ziprasidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00395031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395031.